103 related articles for article (PubMed ID: 38228081)
1. Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma.
Yoon SE; Shin SH; Nam DK; Cho J; Kim WS; Kim SJ
Cancer Res Treat; 2024 Jan; ():. PubMed ID: 38228081
[TBL] [Abstract][Full Text] [Related]
2. Application of circulating tumour DNA in terms of prognosis prediction in Chinese follicular lymphoma patients.
Zhao M; Li Q; Yang J; Zhang M; Liu X; Zhang H; Huang Y; Li J; Bao J; Wang J; Du J; Guan T; Su L
Front Genet; 2023; 14():1066808. PubMed ID: 37152994
[No Abstract] [Full Text] [Related]
3. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.
Kim SJ; Kim YJ; Yoon SE; Ryu KJ; Park B; Park D; Cho D; Kim HY; Cho J; Ko YH; Park WY; Kim WS
Cancer Res Treat; 2023 Jan; 55(1):291-303. PubMed ID: 35240014
[TBL] [Abstract][Full Text] [Related]
5. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
[TBL] [Abstract][Full Text] [Related]
7. Plasma circulating tumor DNA assessment reveals
Li Q; Zhang W; Li J; Xiong J; Liu J; Chen T; Wen Q; Zeng Y; Gao L; Gao L; Zhang C; Kong P; Peng X; Liu Y; Zhang X; Rao J
Biomark Res; 2020; 8():27. PubMed ID: 32695399
[TBL] [Abstract][Full Text] [Related]
8. Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.
Yoon SE; Kim YJ; Shim JH; Park D; Cho J; Ko YH; Park WY; Mun YC; Lee KE; Cho D; Kim WS; Kim SJ
Cancer Res Treat; 2022 Apr; 54(2):597-612. PubMed ID: 34325497
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
10. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
11. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
12. Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.
Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Front Oncol; 2023; 13():1176698. PubMed ID: 37333831
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
14. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
15. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
Fernández-Miranda I; Pedrosa L; Llanos M; Franco FF; Gómez S; Martín-Acosta P; García-Arroyo FR; Gumá J; Horcajo B; Ballesteros AK; Gálvez L; Martínez N; Marín M; Sequero S; Navarro M; Yanguas-Casás N; Calvo V; Rueda-Domínguez A; Provencio M; Sánchez-Beato M
Clin Cancer Res; 2023 Jan; 29(1):209-220. PubMed ID: 36269794
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
18. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
20. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
